Immunosenescence, inflammaging, and cancer immunotherapy efficacy. Issue 9 (2nd September 2022)

• Record Type: Journal Article
• Authors: Rodriguez, Julieta E; Naigeon, Marie; Goldschmidt, Vincent; Roulleaux Dugage, Matthieu; Seknazi, Lauren; Danlos, Francois X; Champiat, Stephane; Marabelle, Aurélien; Michot, Jean-Marie; Massard, Christophe; Besse, Benjamin; Ferrara, Roberto; Chaput, Nathalie; Baldini, Capucine
• Is Part Of: Expert review of anticancer therapy. Volume 22:Issue 9(2022)
• Page Start: 915
• Page End: 926
• Publication Date: 2022-09-02
• Subjects: Immunosenescence -- inflammaging -- older patients -- immune checkpoint inhibitors -- CART cells -- bispecific T-cell engagers; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2022.2098718
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction: Immunosenescence is a progressive remodeling of immune functions associated with a decreased ability of the immune system to set up an efficient immune response, both innate and adaptive, with an increase of highly differentiated T cells at the expense of naive T cells. The incidence and prevalence of most cancers increase with age, which can partly be explained by tumor escape mechanisms and decreased immunosurveillance. Aging is also associated with inflammaging, a low-grade proinflammatory state characterized by an increase in inflammatory mediators. Anti-cancer immunotherapy has profoundly changed the landscape of oncology therapy in the last 10 years. Modern T-cell targeted therapies such as bispecific T cell engagers, CAR-T cells, or immune checkpoint blockers may be theoretically affected by immunosenescence or inflammaging. Areas covered: A bibliographic review through PubMed and Embase was carried out using the following search terms: 'immunosenescence, ' 'immunotherapy, ' 'inflammaging, ' 'bispecific antibodies, ' 'CAR-T cells, ' 'immune checkpoint blockers, ' and 'older patients.' Expert opinion: This review explores the potential impact of immunosenescence and inflammaging on anti-cancer immunotherapy and therapeutic strategies that could counter immune senescence. A more dedicated research on immunosenescence biomarkers in future clinical trials is warranted for the development of new, more effective and safer therapies.